TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
ICLR

ICON PLC

Healthcare · Diagnostics & Research · listed since 1998

167.50$ +0.2% vs. previous close Closing price · As of: Aug 13, 2026
🔔 Watch stock
Add to watchlist

Stock Watch

Stock Watch will tell you what changes at ICON PLC.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 80.10 $ to 202.90 $ · Last price: 167.50 $ (As of: August 13, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 12.9$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. –
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. –
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. –

Performance

Perf. 1M ?Price performance over the last month. -0.30%
Perf. 3M ?Price performance over the last 3 months. 39.20%
Perf. 6M ?Price performance over the last 6 months. 7.10%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). -9.13%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -18.4%
Perf. 1Y ?Price performance over the last 12 months. -5.00%
Perf. 3Y ?Price performance over the last 3 years. -35.18%
Perf. 5Y ?Price performance over the last 5 years. -29.94%
Perf. 10Y ?Price performance over the last 10 years. 118.67%
Perf. Since Inception ?Price performance since the first available trading day (05/15/1998) — with a complete history, that is since the IPO. 2,533.58%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 166.30$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 161.80$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 147.20$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 53.7
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 39.3%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 73.8%

Calculated from the price history · as of 08/14/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. very high 257.7
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. –
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 1.4
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 1.6
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. –
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. 14.4

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. –
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. 9.4%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. –
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? 0.3%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). –

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 56.5%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.4
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. 2.00
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 6 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 1.20%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). -63.30%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. -0.37%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -75.67%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. -15.50%

Dividend

No dividend data is available for this stock yet.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. D (39 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Diagnostics & Research

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
ICON PLC ICLR 12.9 257.7 – – 9.4 -0.4 -5.0
Thermo Fisher Scientific Inc TMO 218.9 33.2 20.9 41.0 17.9 3.9 23.4
Danaher Corporation DHR 144.0 40.2 21.0 58.8 22.9 2.9 -1.8
IDEXX Laboratories Inc IDXX 45.1 41.5 28.9 62.1 31.8 10.4 -14.6
Natera Inc NTRA 44.8 – -26.8 65.1 -12.4 35.9 97.1
Agilent Technologies Inc A 42.3 30.1 20.7 52.6 23.7 6.7 25.1
Waters Corporation WAT 40.6 52.3 42.6 55.2 2.8 7.0 39.3
IQVIA Holdings Inc IQV 40.5 30.5 15.0 33.0 13.6 5.9 27.0
Illumina Inc ILMN 29.1 34.7 29.3 67.9 18.3 -0.8 90.5
Median of companies shown 42.3 37.5 21.0 57.0 17.9 5.9 25.1

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q3 · 2,030.0 $M Q3 2024: Q4 · 2,041.1 $M Q4 2025: Q1 · 2,001.3 $M Q1 2025: Q2 · 2,017.4 $M Q2 2025: Q3 · 2,042.8 $M Q3 2025: Q4 · 2,189.8 $M Q4 2026: Q1 · 2,034.0 $M Q1 2026: Q2 · 2,063.5 $M Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q3 3.35 1.50 2,030 -1.20 9.70 403 359
2024: Q4 3.43 -0.90 2,041 -1.20 12.70 338 277
2025: Q1 3.19 -8.10 2,001 -4.30 7.70 268 239
2025: Q2 3.26 -13.10 2,017 -4.80 9.10 162 128
2025: Q3 3.31 -1.20 2,043 0.60 0.10 409 352
2025: Q4 2.52 -26.50 2,190 7.30 -5.00 234 175
2026: Q1 2.22 -30.40 2,034 1.60 5.20 167 136
2026: Q2 2.35 -27.90 2,064 2.30 3.50 278 235

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 2 of our scanner strategies — each hit links to the scanner.

Growth

Quality & Balance Sheet

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings –
Price Target (average) –
Distance to price –

No price target is available for this stock.

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Aug 11, 2026 Whitaker Anne Clem Director Sell 67 165.51 11,089
Aug 11, 2026 Whitaker Anne Clem Director Sell 590 164.47 97,037
Aug 11, 2026 Whitaker Anne Clem Director Sell 96 163.77 15,722
Aug 11, 2026 Whitaker Anne Clem Director Sell 88 162.72 14,319
Aug 11, 2026 O'Neill Julie Director Sell 73 165.51 12,082
Aug 11, 2026 O'Neill Julie Director Sell 642 164.47 105,590
Aug 11, 2026 O'Neill Julie Director Sell 105 163.77 17,196
Aug 11, 2026 O'Neill Julie Director Sell 95 162.72 15,458
Aug 11, 2026 Murray Ciaran Director Sell 212 165.51 35,088
Aug 11, 2026 Murray Ciaran Director Sell 1,880 164.47 309,204

View all insider transactions →

The company

About the Company

ICON Public Limited Company, eine klinische Forschungsorganisation, erbringt ausgelagerte Entwicklungs- und Vermarktungsdienstleistungen in Irland, Europa, den Vereinigten Staaten und international. Das Unternehmen ist auf die strategische Entwicklung, Steuerung und Analyse von Programmen spezialisiert, die verschiedene Phasen des klinischen Entwicklungsprozesses unterstützen, von der Wirkstoffauswahl bis zu klinischen Studien der Phasen I–IV. Es bietet zudem klinische Entwicklungsdienstleistungen, darunter alle Entwicklungsphasen, peri- und postapprobative Dienste, Datenlösungen sowie Standort- und Patientenzugangsdienste; klinisches Studienmanagement, Beratung, Vertragspersonal, Datenlösungen und Labordienste; sowie kommerzielle Dienstleistungen, darunter klinische Entwicklungsstrategie, Planung und Studiendesign, vollständige Studiendurchführung und Vermarktung nach Markteinführung. Darüber hinaus bietet das Unternehmen Testdienste an, darunter bioanalytische, Biomarker-, Impfstoff-, GMP- und Zentrallabordienste sowie umfassende und funktionale Servicepartnerschaften für Kunden. Ferner bietet das Unternehmen adaptive Studien, Lösungen zur kardialen Sicherheit, klinische und wissenschaftliche Abläufe, Beratung, kommerzielle Positionierung, dezentrale und hybride klinische Studien, frühe klinische Phasen, medizinische Bildgebung, Real-World-Intelligence, Standort- und Patientenlösungen sowie strategische Lösungen. Zusätzlich bietet es Therapeutika für Herz-Kreislauf-Erkrankungen, Erkrankungen des zentralen Nervensystems, endokrine und Stoffwechselstörungen, Hepatologie, Infektionskrankheiten, innere Medizin/Immunologie und Onkologie an. Es bedient die Pharma-, Biotechnologie- und Medizinprodukteindustrie sowie Regierungs- und öffentliche Gesundheitsorganisationen. ICON Public Limited Company wurde 1989 gegründet und hat ihren Hauptsitz in Dublin, Irland.

IPO Year
1998
ISIN
USG4705A1000

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?